ERROR CORRECTION FORM

Sequence Number:

CIBMTR Recipient ID:

Visit:
☐ 100 day
☐ 6 month
☐ year

Today's Date: Month Day 20 Year

Infusion Date: Month Day 20 Year

CIBMTR Center Number:

Initials:

CIBMTR®
CENTER FOR INTERNATIONAL BLOOD & MARROW TRANSPLANT RESEARCH

Myelodysplasia / Myeloproliferative Disorders Post-HSCT Data

Registry Use Only

Sequence Number:

Date Received:

CIBMTR Center Number:

CIBMTR Recipient ID:

Today's Date: Month Day 20 Year

Date of HSCT for which this form is being completed: 🕮 Month Day Year

HSCT type: ☐ autologous ☐ allogeneic, unrelated ☐ allogeneic, related ☐ syngeneic (identical twin)

Product type: ☐ marrow ☐ PBSC ☐ cord blood ☐ other product, specify: _____

Visit: ☐ 100 day ☐ 6 month ☐ 1 year ☐ 2 years ☐ > 2 years, specify:

To be completed in conjunction with a Form 2100 – 100 Days Post-HSCT Data, Form 2200 – Six Months to Two Years Post-HSCT Data, or Form 2300 – Yearly Follow-Up for Greater Than Two Years Post-HSCT Data. Information reported here should reflect the date of last contact as reported in the post-HSCT data collection form, or immediately prior to death.

Disease Assessment at the Time of Best Response to HSCT

Best response is based on response to the HSCT, but does NOT include response to any therapy given for disease relapse or progression post-HSCT. When determining the best response to HSCT, compare the post-HSCT disease status to the status immediately prior to the preparative regimen, regardless of time since HSCT. This comparison is meant to capture the BEST disease status in response to HSCT that occurred in the reporting interval, even if a subsequent disease relapse or progression occurred during the same reporting interval. If a recipient already achieved their best response in a previous reporting interval, confirm the best response and check the box to indicate "date previously reported." 🕮

1. Compared to the disease status prior to the preparative regimen, what was the best response to HSCT since the date of the last report? (Include any therapy planned as of Day 0, but exclude any change in therapy in response to disease assessment.)

1 ☐ complete remission (CR) — requires all of the following, maintained for ≥ 4 weeks:
- bone marrow evaluation: < 5% myeloblasts with normal maturation of all cell lines
- peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000 / mm^3 without myeloid growth factor support; platelets ≥ 100,000 / mm^3 without thrombopoietic support; 0% blasts

2 ☐ hematologic improvement (HI) — requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy:
- HI-E — hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4 units compared to the pre-treatment transfusion number in the previous 8 weeks
- HI-P — for pre-treatment platelet count of > 20,000 / mm^3, platelet absolute increase of ≥ 30,000 / mm^3; for pre-treatment platelet count of < 20,000 / mm^3, platelet absolute increase of ≥ 20,000 / mm^3 and ≥ 100% from pre-treatment level
- HI-N — neutrophil count increase of ≥ 100% from pre-treatment level and an absolute increase of ≥ 500 / mm^3

3 ☐ no response (NR) / stable disease (SD) — does not meet the criteria for at least HI, but no evidence of disease progression

4 ☐ progression from hematologic improvement (prog from HI) — requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.):
- ≥ 50% reduction from maximum response levels in granulocytes or platelets
- reduction in hemoglobin by ≥ 1.5 g/dL
- transfusion dependence

5 ☐ relapse from complete remission (rel from CR) — requires at least one of the following:
- return to pre-treatment bone marrow blast percentage
- decrease of ≥ 50% from maximum response levels in granulocytes or platelets
- transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

6 ☐ progression to AML — ≥ 20% blasts in the bone marrow

CIBMTR Form 2114 (MDS) v1.0 (1–2) July 2007

For internal use only: Document F00501 version 1.0 Replaces: n/a

Mail this form to your designated campus (Milwaukee or Minneapolis). Retain the original at the transplant center.

Fax this form to your designated campus (Milwaukee 414-805-0714 or Minneapolis 612-627-5895).

ERROR CORRECTION FORM

Sequence Number:

CIBMTR Recipient ID:

Visit:
☐ 100 day
☐ 6 month
☐ year

Today's Date: Month Day Year

Infusion Date: Month Day Year

CIBMTR Center Number:

Initials:

CIBMTR Center Number:

CIBMTR Recipient ID:

2. Date best response first began: Month Day Year ☐ date of best response was previously reported

Relapse or Progression Post-HSCT

3. Was a disease relapse or progression detected by any method since the date of the last report?
   1 ☐ yes
   2 ☐ no

4. Date the disease relapse or progression was established in this reporting period: Month Day Year

Most Recent Laboratory Studies

5. Was the bone marrow examined (post-HSCT) since the date of the last report?
   1 ☐ yes →
   2 ☐ no

6. Date of bone marrow exam: Month Day Year

7. Blasts in marrow:
   1 ☐ known → %
   2 ☐ not known

8. Did the recipient have myelofibrosis since the date of the last report?
   1 ☐ yes →
   2 ☐ no

9. Specify the status of marrow fibrosis since the date of the last report:
   1 ☐ unchanged / more severe
   2 ☐ improved
   3 ☐ resolved
   4 ☐ unknown

10. Is a copy of the bone marrow lab report attached?
    1 ☐ yes
    2 ☐ no

Disease Status at the Time of Assessment for this Reporting Period

11. What is the current disease status?
    1 ☐ complete remission
    2 ☐ not in complete remission

12. Date the current disease status was established in this reporting period: Month Day Year

13. Signed: _____
Person completing form

Please print name: _____

Phone: (_____) _____

Fax: (_____) _____

E-mail address: _____

CIBMTR Form 2114 (MDS) v1.0 (2–2) July 2007

For internal use only: Document F00501 version 1.0 Replaces: n/a

Fax this form to your designated campus (Milwaukee 414-805-0714 or Minneapolis 612-627-5895).